Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $12.31, for a total transaction of $24,620.00. Following the sale, the president now directly owns 2,831,260 shares in the company, valued at $34,852,810.60. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.74, for a total transaction of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.25, for a total transaction of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total transaction of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.

Gyre Therapeutics Trading Up 1.4 %

Shares of GYRE opened at $12.28 on Tuesday. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $19.00. The firm’s 50-day simple moving average is $11.32 and its 200 day simple moving average is $12.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after buying an additional 913 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Gyre Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock worth $1,386,000 after purchasing an additional 918 shares in the last quarter. Barclays PLC grew its position in shares of Gyre Therapeutics by 13.5% during the 4th quarter. Barclays PLC now owns 10,543 shares of the company’s stock worth $128,000 after purchasing an additional 1,255 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after purchasing an additional 1,389 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after purchasing an additional 1,996 shares in the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating on the stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.